<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PSA Rising Prostate Cancer Blog &#187; Immunotherapy</title>
	<atom:link href="http://www.psa-rising.com/blog/category/pca/pca-tx/immunotherapy/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.psa-rising.com/blog</link>
	<description></description>
	<lastBuildDate>Thu, 12 Nov 2009 17:35:32 +0000</lastBuildDate>
	<generator>http://wordpress.org/?v=2.8.4</generator>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
			<item>
		<title>Reactions to Provenge Data</title>
		<link>http://www.psa-rising.com/blog/2009/04/reactions-to-provenge-data/</link>
		<comments>http://www.psa-rising.com/blog/2009/04/reactions-to-provenge-data/#comments</comments>
		<pubDate>Tue, 28 Apr 2009 20:50:30 +0000</pubDate>
		<dc:creator>jacquie strax</dc:creator>
				<category><![CDATA[Dendreon]]></category>
		<category><![CDATA[Immunotherapy]]></category>
		<category><![CDATA[Prostate Cancer]]></category>
		<category><![CDATA[Provenge]]></category>
		<category><![CDATA[Vaccines]]></category>

		<guid isPermaLink="false">http://www.psa-rising.com/blog/?p=1264</guid>
		<description><![CDATA[“These results confirm the clinical value of Provenge to prolong survival in patients with advanced prostate cancer,” said Dr. Philip Kantoff, head of the prostate cancer program and chief of the division of solid tumor oncology at the Dana-Farber Cancer Institute and Harvard Medical School, and a principal investigator of the Provenge study, in a [...]]]></description>
		<wfw:commentRss>http://www.psa-rising.com/blog/2009/04/reactions-to-provenge-data/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Investor Interviews Hy Levitsky M.D. on Provenge</title>
		<link>http://www.psa-rising.com/blog/2009/04/investorv-interview-with-hy-levitsky/</link>
		<comments>http://www.psa-rising.com/blog/2009/04/investorv-interview-with-hy-levitsky/#comments</comments>
		<pubDate>Thu, 23 Apr 2009 03:50:15 +0000</pubDate>
		<dc:creator>jacquie strax</dc:creator>
				<category><![CDATA[Biotech companies]]></category>
		<category><![CDATA[Cancer Treatments]]></category>
		<category><![CDATA[Dendreon]]></category>
		<category><![CDATA[Immunotherapy]]></category>
		<category><![CDATA[Prostate Cancer]]></category>
		<category><![CDATA[Provenge]]></category>
		<category><![CDATA[Vaccines]]></category>
		<category><![CDATA[trial results]]></category>
		<category><![CDATA[Add new tag]]></category>
		<category><![CDATA[Dendreon IV board]]></category>
		<category><![CDATA[HY Levitsky M.D.]]></category>
		<category><![CDATA[rufustoehee]]></category>

		<guid isPermaLink="false">http://www.psa-rising.com/blog/?p=1177</guid>
		<description><![CDATA[A four part interview with  Hy Levitsky M.D., professor of oncology and tumor immunology at Johns Hopkins Medical School and co-inventor GVAX anti-cancer vaccine, is posted on Dendreon Investor Village website.
Interview conducted by rufustoehee, a dentist and Dendreon investor, published 4/22/2009.

By way of introduction, Dr Levitsky&#8217;s bio is posted alphabetically downpage among those of other [...]]]></description>
		<wfw:commentRss>http://www.psa-rising.com/blog/2009/04/investorv-interview-with-hy-levitsky/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>A &#8220;Flurry&#8221; of discoveries about the immune system</title>
		<link>http://www.psa-rising.com/blog/2007/04/major-discoveries-about-the-immune-system/</link>
		<comments>http://www.psa-rising.com/blog/2007/04/major-discoveries-about-the-immune-system/#comments</comments>
		<pubDate>Fri, 27 Apr 2007 15:18:08 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[Cancer Treatments]]></category>
		<category><![CDATA[Immunotherapy]]></category>
		<category><![CDATA[immune system]]></category>

		<guid isPermaLink="false">http://psa-rising.com/blog/index.php/2007/04/27/major-discoveries-about-the-immune-system/</guid>
		<description><![CDATA[Today&#8217;s New York Times reports that two groups of scientists have independently made major discoveries about the immune system. One group is led by Allan Bradley and Martin Turner in England and the other by Klaus Rajewsky at Harvard Medical School.
&#8220;These findings demonstrate the importance of this level of control in the immune system and [...]]]></description>
		<wfw:commentRss>http://www.psa-rising.com/blog/2007/04/major-discoveries-about-the-immune-system/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Overview of Immunotherapies for Prostate Cancer</title>
		<link>http://www.psa-rising.com/blog/2007/04/overview-of-immunotherapies-for-prostate-cancer/</link>
		<comments>http://www.psa-rising.com/blog/2007/04/overview-of-immunotherapies-for-prostate-cancer/#comments</comments>
		<pubDate>Fri, 06 Apr 2007 10:58:37 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Clinical trials]]></category>
		<category><![CDATA[Immunotherapy]]></category>
		<category><![CDATA[Prostate Cancer]]></category>
		<category><![CDATA[Vaccines]]></category>

		<guid isPermaLink="false">http://psa-rising.com/blog/index.php/2007/04/06/overview-of-immunotherapies-for-prostate-cancer/</guid>
		<description><![CDATA[For an overview of 3 main types of immunotherapies, or therapeutic vaccines, in trials for prostate cancer see Round Table meeting held on April 1, 2005 in Boston, Massachusetts.  This meeting was paid for by Cell Genesys. Contents (with charts and explanatory cartoons):
FUNDAMENTALS OF TUMOR IMMUNOLOGY
    RELEVANT TO PROSTATE CANCER IMMUNOTHERAPY
Charles [...]]]></description>
		<wfw:commentRss>http://www.psa-rising.com/blog/2007/04/overview-of-immunotherapies-for-prostate-cancer/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Cell Genesys Data for GVAX Vaccine Phase 2 released</title>
		<link>http://www.psa-rising.com/blog/2007/04/cell-genesys-data-for-gvax-vaccine-phase-2-released/</link>
		<comments>http://www.psa-rising.com/blog/2007/04/cell-genesys-data-for-gvax-vaccine-phase-2-released/#comments</comments>
		<pubDate>Fri, 06 Apr 2007 10:50:30 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[GVAX-Cell Genesys]]></category>
		<category><![CDATA[Immunotherapy]]></category>
		<category><![CDATA[Prostate Cancer]]></category>
		<category><![CDATA[Vaccines]]></category>

		<guid isPermaLink="false">http://psa-rising.com/blog/index.php/2007/04/06/cell-genesys-data-for-gvax-vaccine-phase-2-released/</guid>
		<description><![CDATA[Cell Genesys says the 22 patients in their Phase 2 trial of GVAX who  received the most effective tolerable dose &#8212; &#8220;the dose that is comparable to that being employed in the company&#8217;s ongoing Phase 3 program&#8221;&#8211; reached median survival  of 35.0 months.
This trial enrolled men with hormone refractory prostate cancer. Cell Genesys [...]]]></description>
		<wfw:commentRss>http://www.psa-rising.com/blog/2007/04/cell-genesys-data-for-gvax-vaccine-phase-2-released/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
